JENNIFER GARRISON: Open Payments
NPI 1710576905 · CULLMAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$804 in 38 payments from 12 companies in 2025. Trend: 2023 $132 · 2024 $645 · 2025 $804
Food & beverage: $804
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $286 |
| AstraZeneca Pharmaceuticals LP | 5 | $150 |
| ABBVIE INC. | 6 | $142 |
| Otsuka America Pharmaceutical, Inc. | 4 | $57 |
| Novo Nordisk Inc | 2 | $32 |
| PFIZER INC. | 2 | $29 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
| Amgen Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
Products named: CAPLYTA, VRAYLAR, BREZTRI, REXULTI, UBRELVY, NURTEC ODT, Kerendia, AIRSUPRA.
Industry payments across AL — which companies pay providers there.
